(Q45353109)

English

A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice

scientific article published on 7 January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Hepatitis B virus

1 reference

based on heuristic

inferred from title

0 references

1 reference

based on heuristic

inferred from title

Hepatitis B vaccine

1 reference

based on heuristic

inferred from title

10

object named as

Ulrike Protzer

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

author name string

Pascale Buchmann

1

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Claudia Dembek

2

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Larissa Kuklick

3

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Clemens Jäger

4

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Raindy Tedjokusumo

5

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Miriam John von Freyend

6

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Uta Drebber

7

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Zbigniew Janowicz

8

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Karl Melber

9

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

language of work or name

0 references

publication date

7 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

1197-1203

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Immunology of hepatitis B virus and hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Living in the liver: hepatic infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Enhancing the immunogenicity of exogenous hepatitis B surface antigen-based vaccines for MHC-I-restricted T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Combination therapy of active HBsAg vaccination and interferon-alpha in interferon-alpha nonresponders with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Hepatitis B vaccine administered to chronic carriers of hepatitis b surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Simultaneous expression of the S and L surface antigens of hepatitis B, and formation of mixed particles in the methylotrophic yeast, Hansenula polymorpha

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Adjuvants that enhance priming of cytotoxic T cells to a Kb-restricted epitope processed from exogenous but not endogenous hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

ISCOMATRIX adjuvant for antigen delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Role of B cells in antigen presentation of the hepatitis B core

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

Hepatitis B virus nucleocapsid assembly: primary structure requirements in the core protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

based on heuristic

inferred from DOI database lookup

High-level hepatitis B virus replication in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.074

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2012.12.074

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45353109&oldid=2075539897"